Cantor Raises Jazz Pharmaceuticals Price Target On Xyrem Scenario Analysis

In a research report issued today, Cantor analyst Irina Rivkind assigned a Hold rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and raised her price target to $197 (from $151), which represents a potential upside of 16.5% from where the stock is currently trading.

Koffler wrote, “We are raising our price target to $197 from $151 after conducting scenario analysis around Xyrem durability: We assess two possible outcomes to arrive at our new blended price target: (1) Progression of Flamel’s micropump drug with market entry in mid-2019 to capture 30% of the Xyrem franchise prescriptions by 2024. If we incorporate this competitor into our estimates and extend our DCF to 2024 (while lowering risk-rate from 14% to 12%), we arrive at a hypothetical $182 valuation for JAZZ. This represents a more realistic scenario than near-term generic entry, in our view, and we have made this our base- case assumption. (2) Jazz settles with Roxane in 2015 for a generic launch date between 2024-2033, switches patients to JZP-386, and no Flamel competition. Xyrem/JZP-386 sales exceed $2.0B in 2024. Under this scenario we would expect the stock to approach $211/share, with some potential premium for the company’s anticipated cash accumulation.”

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Irina Rivkind Koffler has a total average return of 15.3% and a 63.5% success rate. Rivkind Koffler has a 120.8% average return when recommending JAZZ, and is ranked #162 out of 3355 analysts.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts